Shareholder Great Point Partners LLC Has Increased Ptc Therapeutics INC (PTCT) Stake

March 14, 2018 - By Kenneth Lin

Investors sentiment increased to 1.71 in Q3 2017. Its up 0.79, from 0.92 in 2017Q2. It is positive, as 13 investors sold PTCT shares while 28 reduced holdings. 25 funds opened positions while 45 raised stakes. 32.89 million shares or 5.85% more from 31.07 million shares in 2017Q2 were reported. Great West Life Assurance Can reported 4,580 shares or 0% of all its holdings. Nationwide Fund, a Pennsylvania-based fund reported 21,718 shares. Consonance Capital Mngmt Limited Partnership has invested 8.73% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Blackrock, New York-based fund reported 3.14M shares. State Of Wisconsin Investment Board invested in 0% or 24,000 shares. The New York-based Ghost Tree Ltd Liability has invested 0.42% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Los Angeles Mngmt And Equity has 11,460 shares for 0% of their portfolio. Great Point Partners Limited Company invested in 4.28% or 1.10M shares. 19,270 were reported by Tudor Et Al. 23,200 are owned by Canada Pension Plan Invest Board. Proshare Advsrs Ltd Liability has 26,069 shares. Usa Portformulas has invested 0.11% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). 247,249 were reported by Frontier Mgmt Ltd Liability. American Century holds 0% or 196,722 shares in its portfolio. Sg Americas Ltd Company invested in 0.01% or 41,694 shares.

Since January 3, 2018, it had 0 insider purchases, and 4 insider sales for $61,523 activity. Shares for $40,207 were sold by Peltz Stuart Walter. Shares for $7,280 were sold by Utter Christine Marie on Wednesday, January 3.

Jeffrey Jay increased its stake in Ptc Therapeutics Inc (PTCT) by 323.08% based on its latest 2017Q3 regulatory filing with the SEC. Great Point Partners Llc bought 840,000 shares as the company’s stock declined 3.95% while stock markets rallied. The hedge fund run by Jeffrey Jay held 1.10M shares of the health care company at the end of 2017Q3, valued at $22.01 million, up from 260,000 at the end of the previous reported quarter. Great Point Partners Llc who had been investing in Ptc Therapeutics Inc for a number of months, seems to be bullish on the $1.27B market cap company. The stock increased 1.67% or $0.5 during the last trading session, reaching $30.39. About 1.03 million shares traded or 10.34% up from the average. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 104.51% since March 14, 2017 and is uptrending. It has outperformed by 87.81% the S&P500.

Great Point Partners Llc, which manages about $935.83 million and $514.03 million US Long portfolio, decreased its stake in Zogenix Inc by 1.42 million shares to 1.02M shares, valued at $35.80 million in 2017Q3, according to the filing. It also reduced its holding in Synergy Pharmaceuticals Del (NASDAQ:SGYP) by 3.95 million shares in the quarter, leaving it with 3.27M shares, and cut its stake in Adamas Pharmaceuticals Inc (NASDAQ:ADMS).

More important recent PTC Therapeutics, Inc. (NASDAQ:PTCT) news were published by: which released: “PTC Therapeutics Receives Formal Dispute Resolution Request Decision from the …” on February 20, 2018, also published article titled: “PTC Therapeutics Launches Fourth Annual STRIVE Grant Award Program for …”, published: “PTC Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results …” on March 06, 2018. More interesting news about PTC Therapeutics, Inc. (NASDAQ:PTCT) was released by: and their article: “Earnings Reaction History: PTC Therapeutics, Inc., 40.0% Follow-Through …” with publication date: March 06, 2018.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage

Among 12 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 have Buy rating, 1 Sell and 7 Hold. Therefore 33% are positive. PTC Therapeutics had 38 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Wednesday, January 20 by Credit Suisse. The firm earned “Hold” rating on Thursday, September 14 by RBC Capital Markets. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) earned “Hold” rating by Cowen & Co on Friday, June 30. RBC Capital Markets maintained the shares of PTCT in report on Friday, July 31 with “Outperform” rating. The company was maintained on Wednesday, March 7 by Barclays Capital. The rating was downgraded by JP Morgan on Monday, October 9 to “Underweight”. The company was maintained on Friday, October 16 by Oppenheimer. JP Morgan upgraded the stock to “Neutral” rating in Thursday, November 16 report. As per Wednesday, February 24, the company rating was maintained by Wedbush. The rating was downgraded by JP Morgan on Tuesday, February 23 to “Neutral”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: